Clinical trials: Vaccination Adverse Event
Influenza, Vaccines Adverse Reaction
Surveillance for Adverse Events Following Influenza Immunization
Influenza vaccines are continuously modified to adjust to the virus antigenic shifts or drifts, and its safety profile may vary.
- Trial name
- NCT01318876
- Where
- 7 sites in Canada
- Volunteers
- 7,645 people, healthy volunteers welcome
- Sponsor
- PHAC/CIHR Influenza Research Network
COVID-19 Vaccination
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.
- Trial name
- NCT06613984
- Testing
- Bretovameran
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Vaccination Adverse Event
A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older
To monitor the safety of Shanghai Institute of Biological Products Company's influenza vaccine in subjects aged 3 years and older through Adverse Events Following Immunization Surveillance System of China.
- Trial name
- NCT02133456
- Volunteers
- 166,240 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Cardiovascular Disease, Dementia
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults.
- Trial name
- DAN-ZOSTER (NCT07485283)
- Testing
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Where
- 2 sites in Denmark
- Volunteers
- 168,460 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
HIV
Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes
Our research is part of the global effort to develop a vaccine against HIV. We aim to develop a non-invasive, needle-free 'transcutaneous' vaccine.
- Trial name
- CUT*HIVAC001 (NCT02075983)
- Testing
- GTU®-multiHIV B clade
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pain, Quality of Life
FLUAD® vs. Fluzone® High-Dose Study
The overall aim of the study is to compare safety and immunogenicity of inactivated influenza vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone® High-Dose) vaccine in persons ≥65 years (20% aged…
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug
- Trial name
- NCT03183908
- Testing
- FLUAD®, Fluzone® High-Dose
- Where
- 4 sites in United States
- Volunteers
- 757 people, healthy volunteers welcome
- Sponsor
- Duke University
Mobile Apps, Immunization
Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform
Methods Study Procedures A two-centred randomized control trial (RCT) was conducted to evaluate the use of safety reporting via a mobile app compared to safety reporting via web-based CANVAS notifications amongst individuals…
- Conditions
- Mobile Apps, Immunization, Adverse Event Following Immunisation
- Trial name
- NCT05794113
- Testing
- Mobile app - CanImmunize, Web based notification
- Where
- Canada
- Volunteers
- 2,408 people, healthy volunteers welcome
- Sponsor
- The Ottawa Hospital
Rabies Vaccine Allergy, Vaccination Adverse Event
The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use
The objective of this study was to achieve the post-marketing safety and immunogenicity research of Speeda® rabies vaccine for human use from Chengda Bio
- Conditions
- Rabies Vaccine Allergy, Vaccination Adverse Event, Anti-D Antibodies
- Trial name
- NCT01821911
- Testing
- Zagreb2-1-1, Essen
- Where
- 3 sites in China
- Volunteers
- 10,500 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
HIV
Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses
UKHVC Spoke 003 is a randomised Phase I, two centre study which will explore the impact of shortening a vaccination regimen using deoxyribonucleic acid (DNA) (CN54ENV and ZM96GPN), Modified Vaccinia Ankara - C (MVA-C) and…
- Trial name
- UKHVCSpoke003 (NCT01922284)
- Testing
- DNA, MVA-C, CN54rgp140
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pain, Vaccination Adverse Event
A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination
The aim of this study was to assess the acceptability and usability of a newly developed intradermal device in healthy adults
- Trial name
- NCT01963338
- Testing
- Intradermal injection in the forearm (0,1cc NaCl 0,9%), Intradermal injection in the upper arm (0,1cc NaCl 0,9%), Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)
- Where
- Belgium
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Adverse Drug Event
Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers
Limited large-scale studies have been conducted to investigate the adverse effects of COVID-19 vaccine in Latin America, particularly among the healthcare worker (HCW) population in Ecuador.
- Trial name
- NCT05113472
- Testing
- Pfizer-BioNTech COVID-19 vaccine
- Where
- Ecuador
- Volunteers
- 1,291 people, healthy volunteers welcome
- Sponsor
- Respiralab